After the benchmark S&P/ASX 200 surged 7.5 per cent in 2024, investors are looking to see where the growth will come from in ...

The advent of a Trump presidency is accelerating a divergence on digital currencies between the world’s two largest economies ...

Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

ASX tech rocked a 50pc gain in 2024, Archer Materials shone in December, and Dubber and Brainchip cashed in on major ...

ASX 200 edges up on a tech rally, while miners struggle, Barrick Gold threatens a Mali shutdown, and Bitcoin bounces back.

Kalamazoo Resources led materials sector gainers this morning as the release of drill assays from its Mallina West gold ...

Opyl has entered a joint venture with X Firm to market its TrialKey platform in key markets, while Dimerix has inked another ...

Riversgold’s (ASX:RGL) rock chip sampling is defining multiple multi-metal targets across the ~25 km strike of the Saint John ...

Fraser Palamara details Dimerix's (ASX:DXB) deal with Japanese pharmaceutical company FUSO to fight a deadly kidney disease.

ASX climbs while Bitcoin surges past US$102k thanks to Trump’s crypto push and Capricorn hits a gold output record.

Special Report: James Bay Minerals is progressing exploration at its Independence gold project in Lander County, Nevada, with ...

Stockhead's Sarah Hughan unpacks clinical stage biotech company AdAlta, set to unlock value from its AD-214 asset and expand its pipeline through its "East to West" cell therapy strategy in 2025.